Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

UNITY Biotechnology (NASDAQ:UBX) stock fell 30% after the company's mid-stage trial for its diabetic macular edema treatment ...

Chardan lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $6 and keeps a Buy rating on the shares after the company ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Unity Biotechnology (NASDAQ:UBX – Get Free Report) had its price objective cut by research analysts at Chardan Capital from $6.00 to $4.00 in a research report issued on Tuesday,Benzinga reports. The ...

H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Unity Biotechnology (UBX) to $4 from $8 and keeps a Buy rating on ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

UBX] has announced top-line results from the Phase IIb ASPIRE clinical trial of intravitreal UBX1325 (foselutoclax) in ...

Source: Unity Biotechnology, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of its lead candidate, intravitreal UBX1325 compared with Regeneron’s ...